"OpportunityAnalyzer: Uveitis - Opportunity Analysis and Forecasts to 2017" Published

Uveitis is an expanding market currently dominated by corticosteroid treatment options as well as off-label immunosuppressive and biologic drugs. Since the conventional corticosteroid treatment is only effective in 50-60% of patients a significant number of patients can be targeted with the new treatment options. While anterior uveitis patients represent the majority of patients, all but one of the new treatments in late stage clinical development target the intermediate, posterior and pan uveitis patient segment. The uveitis market is expected to grow between 2012 and 2017, due to the introduction of biologic drugs as well as a diversification of administrative routes. Market growth is created by the increase in treatment costs and will continue beyond the forecasted time period. The new treatments will target some key unmet needs but opportunities will remain for drugs capable of permanently inhibiting ocular inflammation as well as offering an improved safety profile.

Full Report Details at
- http://www.fastmr.com/prod/760050_opportunityanalyzer_uveitis_opportunity_analysis.aspx?afid=302

Highlights

Key Questions Answered

* The uveitis market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the uveitis market?
* The late-stage uveitis pipeline is filled with diverse molecules and routes of administration. Which drug will have a significant impact on the uveitis market. Which of these drugs will have the highest CAGR, and why?
* The current uveitis market is dominated by corticosteroids as well as off-label immunosuppressive and biologic drugs. How will the introduction of biologic drugs change the treatment landscape once reimbursement is not a problem anymore? How will the drug treatment rates change over the next five years? What are the key drivers and barriers to this change?

Key Findings

* The main driver of the expansion of the uveitis market will be the introduction of biologic drugs, which will increase the market size significantly. The introduction of new ocular administration routes will strengthen the market growth further.
* An additional driver for the uveitis market is the assignment of orphan drug status to several uveitis drugs.
* The biggest barrier for the introduction of the more costly treatment options like biologics will be reimbursement especially in the European markets. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively.
* Pipeline drugs developed by small to mid-size pharma companies represent a good opportunity for companies to enter the uveitis market and to strengthen their ophthalmology department.

Scope

* Overview of uveitis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- OpportunityAnalyzer: Opioid-Induced Constipation - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017
- OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017